Yüklüyor......
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
Dendritic cells (DCs) are antigen-presenting cells involved in T cell activation and differentiation to regulate immune responses. Lipoimmunogens can be developed as pharmaceutical lipoproteins for cancer immunotherapy to target DCs via toll-like receptor 2 (TLR2) signaling. Previously, we construct...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7225995/ https://ncbi.nlm.nih.gov/pubmed/32231003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040810 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|